Christopher Cabell - President & Head of R&D at Inhibikase Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
President & Head of R&D
Stock Symbol
IKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Christopher Cabell since 10/28/2024

Holdings reported by Christopher Cabell for Inhibikase Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 1.01M $1.7M $1.68 Feb 21, 2025 Direct
Stock Option (Right to Buy) 1.1M Feb 21, 2025 Direct Common Stock

Transactions reported by Christopher Cabell for Inhibikase Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.